JC04 Rec'd PCT/PTO 2 9 MAY 2001 PC

02763224

c:as:7024-497:128550

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

y In re U. S. application of:	)	Before the Examiner
David A. Sanders et al.	)	(Unassigned)
	)	
Serial No. 09/762224	)	
Filing Date: February 2, 2001	)	May 22, 2001
Thing Date. Teordary 2, 2001	)	Way 22, 2001
PSEUDOTYPED RETROVIRUSES AND	)	
STABLE CELL LINES FOR THEIR	)	
PRODUCTION	)	

## **INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to the duty of disclosure embodied in 37 C.F.R. §1.56, Applicant wishes to bring to the attention of the Examiner the references listed on the enclosed Information Disclosure Statement (PTO Form 1449). These references have not been previously submitted in this application, and have not been heretofore cited by the Examiner in this case. A copy of each reference is enclosed in accordance with 37 C.F.R. § 1.98(a).

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on:

May 22, 2001
(Date of Deposit)

Jason J. Schwartz

Name of Register of Representative

May 22, 2001

May 22, 2001

Date of Signature

The identified formation, taken alone or in combination with other art, provides information relating to the subject matter of the invention, but fails to teach, disclose or suggest the present invention. The filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in § 1.56(b).

1

This information is being submitted more than three months after the filing date of the application, but before the mailing of a first Office Action on the merits. It is therefore believed that no fee is required for consideration of the submitted items. However, should any fee be required, please charge such fee to Deposit Account No. 23-3030, but not to include any payment of issue fees.

Respectfully Submitted

By:

Jason J. Schwartz

Reg. No. 43,910

Woodard, Emhardt, Naughton,

Moriarty & McNett

Bank One Center/Tower

111 Monument Circle, Suite 3700

Indianapolis, Indiana 46204-5137

(317) 634-3456

42:as:7	024 40	7-129	255

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Page 1 of 2

ATTY. DOCKET NO.	SERIAL NO.	
7024-497	09/762,224	
APPLICANT		
David A. Sanders et al.		
FILING DATE	GROUP	

February 2, 2001

U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	4,912,030	Mar. 1990	Weiss et al.	435	5	
	5,185,440	Feb. 1993	Davis et al.	536	237.2	
	5,278,056	Jan. 1994	Bank et al.	435	172.3	·
	5,491,084	Feb. 1996	Chalfie et al.	435	189	
	5,503,974	Apr. 1996	Gruber et al.	435	5	
	5,512,421	Apr. 1996	Burns et al.	435	320	
	5,591,624	Jan. 1997	Barber et al.	435	240.2	
	5,681,746	Oct. 1997	Bodner et al.	435	350	
	5,723,287	Mar. 1998	Russell et al.	435	5	
	5,723,333	Mar. 1998	Levine et al.	435	69.1	
	5,739,018	Apr. 1998	Miyanohara et al.	435	172.3	
	5,747,243	May 1998	Gruber et al.	435	5	
	5,750,396	May 1998	Yang et al.	435	357	
	5,910,434	June 1999	Rigg et al.	435	172.3	
					·	


## **FOREIGN DOCUMENTS**

DOCUMENT	DATE COUNTRY	CLASS	SUBCLASS	TRANSLATION			
 NUMBER						YES	NO
						-	
			<u> </u>				
 <u> </u>				<u> </u>		<u> </u>	

**EXAMINER** 

**DATE CONSIDERED** 

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Page 2 of 2

ATTY. DOCKET NO. SERIAL NO. 7024-497 09/762,224 **APPLICANT** David A. Sanders et al. FILING DATE GROUP February 2, 2001

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

 OTHER DOCUMENTS (Including Author, Title, Date, Perlinent Pages, Etc.)
Will, C., et al., Marburg Virus Gene 4 Encodes the Virion Membrane Protein, a Type I Transmembrane
Glycoprotein, J. of Virology, 67:3:1203-1210 (1993).
Sanchez, A., et al., Sequence Analysis of the Ebola Virus Genome: Organization, Genetic Elements,
and Comparison with the Genome of Marburg Virus, Virus Research, 29:215-240 (1993).
Lopez, S., et al., <i>Nucleocapsid-Glycoprotein Interactions Required for Assembly of Alphaviruses</i> , J. of Virology, 68:3:1316-1323 (1994).
Riviere, I, et al., Effects of Retroviral Vector Design on Expression of Human Adenosine Deaminase in
Murine Bone Marrow Transplant Recipients Engrafted with Genetically Modified Cells, Proc. Nat'l. Acad. Sci. USA, 92:6733-6737 (1995).
Sharma, S., et al., Efficient Infection of a Human T-Cell Line and of Human Primary Peripheral Blood Leukocytes with a Pseudotyped Retrovirus Vector, Proc. Nat'l Acad. Sci. USA, 93:21:11842-11847 (1996).
Ory, D. S., et al., A Stable Human-Derived Packaging Cell Line for Production of High Titer
Retrovirus/Vesicular Stomatitis Virus G Pseudotypes, Proc. Nat'l. Acad. Sci. USA, 93:11400-11406
(1996).
Kuhn, R. J., et al., <i>Chimeric Sindbis-Ross River Viruses to Study Interactions Between Alphavirus Nonstructural and Structural Regions</i> , J. of Virology, 70:11:7900-7909 (1996).
Takada, A., et al., A System for Functional Analysis of Ebola Virus Glycoprotein, Proc. Nat'l. Acad. Sci. USA, 94:14764-14769 (1997).
Grignani, F., et al., High-Efficiency Gene Transfer and Selection of Human Hematopoietic Progenitor Cells with a Hybrid EBV/Retroviral Vector Expressing the Green Fluorescence Protein, Cancer Research, 58:14-19 (1998).
Yang, Z., et al., Distinct Cellular Interactions of Secreted and Transmembrane Ebola Virus Glycoproteins, Science, 279:1034-1037 (1998).
Wool-Lewis, R. and Bates, P., Characterization of Ebola Virus Entry by Using Pseudotyped Viruses: Identification of Receptor-Deficient Cell Lines, J. of Virology, 72:4:3155-3160 (1998).
 Hatzhoannou, T., et al., Incorporation of Fowl Plague Virus Hemagglutinin into Murine Leukemia Virus
Particles and Analysis of the Infectivity of the Pseudotyped Retroviruses, J. of Virology, 72:6:5313-5317 (1998).

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through		

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.